Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry
| Autoři | |
|---|---|
| Rok publikování | 2013 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Clinical Rheumatology |
| Fakulta / Pracoviště MU | |
| Citace | |
| Doi | http://dx.doi.org/10.1007/s10067-013-2303-6 |
| Obor | Ostatní lékařské obory |
| Klíčová slova | Abatacept; Registry; Rheumatoid arthritis |
| Popis | The Czech national registry ATTRA collects data from patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenile idiopathic arthritis, treated with the biologic drugs. ATTRA is a prospective centralized computerized registry of patients with a focus on efficacy, safety, and quality of life data. Abatacept is approved as a second-line agent which can be prescribed after a failure of at least one TNF-alfa inhibitor. Data of patients treated with abatacept has been collected since 2008. A statistical analysis of the group of RA patients treated with abatacept was performed recently. ATTRA registered 162 patients with RA treated with abatacept, the mean age 51.0 +/- 12.2 (median 53.1, 19-74 years), the mean duration of the disease was 14 +/- 9.1, median 11.3 years (0-41). One hundred thirty patients (80.2 %) were female. The mean DAS28 was at week 0, 5.9 +/- 1.1, at week 16, 4.1 +/- 1.4, at week 24, 3.8 +/- 1.2, at week 36, 3.6 +/- 1.3, and at week 52, 3.5 +/- 1.2. DAS28 remission was achieved at week 16 in 15.8 %, at week 24 in 10 %, at week 36 in 20.9 %, and at week 52 in 20.8 % of patients. Of those patients with a DAS28 < 2.6 (remission) at week 16, 58.3 % remained in remission at the week 52. Of those patients with DAS28 > 5.1 (high disease activity) at the week 16, only 41.7 % had DAS > 5.1 at week 52. One year on treatment survival was 82 %. Altogether 50 non-serious adverse events (AE) were reported in 36 patients (22 %) and 11 serious AE in 10 patients (6 %) with the most common being infections (31) and skin rashes (5). Just one non-serious allergic reaction was reported. Data from the ATTRA registry confirms a good overall efficacy and safety profile and a very good on drug survival with abatacept. |